Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 19/20 | 0.70 |
| ▸ | BMPR1A | P36894 | 12/20 | 0.70 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.62 |
| ▸ | ACVR1B | P36896 | 7/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 6/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26867287 | 0.94 | ACVR1 (0.69) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17441845 | 0.93 | ACVR1 (0.68) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17441841 | 0.92 | ACVR1 (0.69) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17448562 | 0.87 | ACVR1 (0.74) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL26867273 | 0.85 | ACVR1 (0.70) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17442388 | 0.84 | ACVR1 (0.69) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17442424 | 0.84 | ACVR1 (0.69) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL26867251 | 0.84 | ACVR1 (0.69) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL19123447 | 0.84 | ACVR1 (0.72) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17441857 | 0.83 | ACVR1 (0.85) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | ACVR1 13/4885BMPR1A 8/4885ACVRL1 22/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | ACVR1 16/4885BMPR1A 10/4885ACVRL1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.